THC (tetrahydrocannabinol) is the primary psychoactive cannabinoid in cannabis. CBD (cannabidiol) is non-intoxicating and binds differently at cannabinoid receptors. Both interact with the endocannabinoid system. NIH/NIDA research-backed overview with hedge language on effects.
THC and CBD are the two most prominent cannabinoids in cannabis. THC — delta-9-tetrahydrocannabinol — is the primary psychoactive compound; it binds with high affinity to the CB1 cannabinoid receptor and produces the characteristic intoxicating effect of cannabis. CBD — cannabidiol — is non-intoxicating; it binds weakly at CB1, has more complex interactions at CB2 and non-cannabinoid receptors, and is associated in clinical research with anti-inflammatory and anti-seizure activity (FDA-approved as Epidiolex for specific seizure disorders). Both cannabinoids interact with the endocannabinoid system — a network of receptors and signaling molecules in mammalian biology. This guide describes the pharmacology of each cannabinoid using language consistent with peer-reviewed research (NIH/NIDA/NLM) and avoids unverified health claims.
THC is the principal psychoactive cannabinoid in cannabis. It binds with high affinity to the CB1 cannabinoid receptor — concentrated in the central nervous system — producing the characteristic intoxicating effect. THC is also a partial agonist at CB2 (more peripheral, immune-system-associated). Lab-tested adult-use cannabis flower in Minnesota typically reports 15-30% THC by weight. The federally legal hemp limit for THC is 0.3% by dry weight under the 2018 Farm Bill.
CBD is non-intoxicating. It binds weakly to CB1 (the receptor responsible for THC's psychoactive effect) and has complex activity at CB2, plus non-cannabinoid targets including serotonin 5-HT1A, TRPV1, and PPAR receptors. CBD is FDA-approved as Epidiolex for specific seizure disorders (Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex) per FDA labeling. Research literature also examines CBD for anti-inflammatory and anxiolytic effects, but clinical evidence outside the Epidiolex indications is limited.
“Epidiolex (cannabidiol) is FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older.”
The endocannabinoid system (ECS) is a signaling network present in all mammals, comprising cannabinoid receptors (CB1, CB2), endogenous cannabinoid molecules (anandamide, 2-AG), and the enzymes that synthesize and degrade them. The ECS modulates appetite, pain perception, mood, immune function, and many other processes. Plant cannabinoids (phytocannabinoids) including THC and CBD interact with this system to produce their effects.
THC produces intoxicating effect (euphoria, altered perception, increased appetite, motor impairment at higher doses) via strong CB1 agonism. CBD does not produce intoxication. Some research suggests CBD may modulate THC's effects when co-consumed — potentially reducing anxiety or paranoia at certain ratios — but clinical evidence is limited. Cannabis cultivars with significant CBD content (Type II balanced, Type III CBD-dominant) tend to produce a less-intoxicating experience than equivalent THC-content cultivars.
Beyond THC and CBD, the cannabis plant contains many minor cannabinoids — CBN (cannabinol, mildly sedating, degradation product of THC), CBG (cannabigerol, often called 'the precursor cannabinoid'), CBC (cannabichromene), THCV (tetrahydrocannabivarin, varin variant of THC), and others. Modern lab COAs increasingly report the full cannabinoid profile.
A cannabis batch's certificate of analysis (COA) reports cannabinoid potency by weight. For Minnesota cannabis, you'll typically see THC, THCA (the acid form that decarboxylates to THC), CBD, CBDA, CBN, CBG, and total THC (THC + 0.877×THCA). 'Total THC' is the figure that matters for psychoactive potency once decarboxylated by heat. Lab tests also report terpene profile and any contaminants (heavy metals, pesticides, microbials).